vir-7832
mAbexperimentalCOVID-19
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 3, 2020 (NCT04746183)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04746183 | Phase 1/Phase 2 (Phase 2) | Jul 3, 2020 | Moorgreen Hospital, Southampton, Royal Liverpool & Broadgreen University Hospitals NHS Truts, University of Cambridge, University of Liverpool |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Royal Liverpool & Broadgreen University Hospitals NHS Truts | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of Liverpool | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1